ILF/CIPHER webinar

Report Back from PADO 3

Tuesday, 28 February 2017
10:00-11:00 EST / 16:00-17:00 CET / 20:30-21:30 IST
Collaborative and coordinated action to optimize paediatric ARVs

Key formulations are prioritized in the context of a public health approach

Priority formulations are reliably supplied to countries

Technical/research work undertaken to support development of the priority formulations

Priority formulations are procured via a pooled mechanism

Priority formulations are included in the optimal formulary for selection
ILF/CIPHER webinar
Report back from the paediatric week

Thursday, 15 December 2016

Recording available at: https://youtu.be/R16BKnFwCEg
Today’s meeting

• Ensure timely updates from PADO 3 and PAWG to ARV manufacturers
• Facilitate the delivery of industry feedback to these key paediatric ARV initiatives
• Convened by the International AIDS Society ILF and CIPHER, with key contributions from the WHO
Paediatric HIV at the IAS

Industry Liaison Forum (ILF)
• Fast-track the development of paediatric HIV medicines (focusing on the most needed paediatric ARV formulations) through incentivising their development.

Collaborative Initiative for Paediatric HIV Education and Research (CIPHER)
• Promote and invest in targeted research to address priority knowledge gaps in paediatric HIV
• Convene stakeholders and establish collaboration mechanisms to strengthen communication, knowledge transfer and exchange among paediatric HIV cohorts
• Support evidence-informed clinical, policy and programmatic decision making through advocacy and outreach.
Global Accelerator for Paediatric Formulations

- Led by Global Pediatric Antiretroviral Commitment-to-Action (CTA) partners

- New collaborative framework to fast track development of paediatric drug formulations (HIV as a starting point, but also viral hepatitis and tuberculosis)

- Includes a set of recommendations for regulatory agencies and industry, as well as an innovative financing mechanism

- Key milestones in 2016 include a series of expert meetings (reports available [here](#) and [here](#)), which led to the development of an action plan in three stages (presented during the Geneva Paediatric HIV Week in December 2016)

- The action plan is being reviewed for endorsement by CTA partners; once validated, the plan will be shared with the broader group of stakeholders and implementation of the action plan will start...
Today’s agenda

16:00 CET Welcome and introduction
5 minutes Sébastien Morin (IAS)

16:05 CET PADO 3 priorities
25 minutes Martina Penazzato (WHO)
Philippa Easterbrook (WHO)

16:30 CET PAWG plans
10 minutes Martina Penazzato (WHO)

16:40 CET Q&A (from the chat)
15 minutes Facilitated by Sébastien Morin (IAS)

16:55 CET Closing remarks
5 minutes Sébastien Morin (IAS)

Historically focused on paediatric HIV drugs; now looking at paediatric hepatitis and tuberculosis drugs as well!
Housekeeping announcements

• Questions will be received through the WebEx chat function (alternatively emails to sebastien.morin@iasociety.org)

• Only speakers’ audio will be turned on; other participants will be muted

• The meeting is being recorded; the recording will be posted on the ILF website (www.iasociety.org/ilf)